Mark W Clemens1, L Jeffrey Medeiros1, Charles E Butler1, Kelly K Hunt1, Michelle A Fanale1, Steven Horwitz1, Dennis D Weisenburger1, Jun Liu1, Elizabeth A Morgan1, Rashmi Kanagal-Shamanna1, Vinita Parkash1, Jing Ning1, Aliyah R Sohani1, Judith A Ferry1, Neha Mehta-Shah1, Ahmed Dogan1, Hui Liu1, Nora Thormann1, Arianna Di Napoli, Arianna DiNapoli1, Stephen Lade1, Jorge Piccolini1, Ruben Reyes1, Travis Williams1, Colleen M McCarthy1, Summer E Hanson1, Loretta J Nastoupil1, Rakesh Gaur1, Yasuhiro Oki1, Ken H Young1, Roberto N Miranda2. 1. Mark W. Clemens, L. Jeffrey Medeiros, Charles E. Butler, Kelly K. Hunt, Michelle A. Fanale, Jun Liu, Rashmi Kanagal-Shamanna, Jing Ning, Summer E. Hanson, Loretta J. Nastoupil, Yasuhiro Oki, Ken H. Young, and Roberto N. Miranda, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Horwitz, Neha Mehta-Shah, Ahmed Dogan, and Colleen M. McCarthy, Memorial Sloan Kettering Cancer Center, New York, NY; Dennis D. Weisenburger, City of Hope National Medical Center, Duarte, CA; Elizabeth A. Morgan, Brigham and Women's Hospital and Harvard Medical School; Aliyah R. Sohani and Judith A. Ferry, Massachusetts General Hospital and Harvard Medical School, Boston, MA; Vinita Parkash, Yale School of Medicine, New Haven, CT; Hui Liu, Xuzhou Medical College, Xuzhou, People's Republic of China; Nora Thormann, Fundacao Universitaria Mario Martins, Porto Alegre, Brazil; Arianna DiNapoli, Sant'Andrea Hospital, Sapienza University, Rome, Italy; Stephen Lade, University of Melbourne, Melbourne, Victoria, Australia; Jorge Piccolini, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Ruben Reyes, Kansas University Medical Center, Kansas City, KS; Travis Williams, St Luke's Mountain States Tumor Institute, Meridian, ID; and Rakesh Gaur, St Luke's Hospital, Kansas City, MO. 2. Mark W. Clemens, L. Jeffrey Medeiros, Charles E. Butler, Kelly K. Hunt, Michelle A. Fanale, Jun Liu, Rashmi Kanagal-Shamanna, Jing Ning, Summer E. Hanson, Loretta J. Nastoupil, Yasuhiro Oki, Ken H. Young, and Roberto N. Miranda, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Horwitz, Neha Mehta-Shah, Ahmed Dogan, and Colleen M. McCarthy, Memorial Sloan Kettering Cancer Center, New York, NY; Dennis D. Weisenburger, City of Hope National Medical Center, Duarte, CA; Elizabeth A. Morgan, Brigham and Women's Hospital and Harvard Medical School; Aliyah R. Sohani and Judith A. Ferry, Massachusetts General Hospital and Harvard Medical School, Boston, MA; Vinita Parkash, Yale School of Medicine, New Haven, CT; Hui Liu, Xuzhou Medical College, Xuzhou, People's Republic of China; Nora Thormann, Fundacao Universitaria Mario Martins, Porto Alegre, Brazil; Arianna DiNapoli, Sant'Andrea Hospital, Sapienza University, Rome, Italy; Stephen Lade, University of Melbourne, Melbourne, Victoria, Australia; Jorge Piccolini, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Ruben Reyes, Kansas University Medical Center, Kansas City, KS; Travis Williams, St Luke's Mountain States Tumor Institute, Meridian, ID; and Rakesh Gaur, St Luke's Hospital, Kansas City, MO. roberto.miranda@mdanderson.org.
Abstract
PURPOSE: Breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is a rare type of T-cell lymphoma that arises around breast implants. The optimal management of this disease has not been established. The goal of this study is to evaluate the efficacy of different therapies used in patients with BI-ALCL to determine an optimal treatment approach. PATIENTS AND METHODS: In this study, we applied strict criteria to pathologic findings, assessed therapies used, and conducted a clinical follow-up of 87 patients with BI-ALCL, including 50 previously reported in the literature and 37 unreported. A Prentice, Williams, and Peterson model was used to assess the rate of events for each therapeutic intervention. RESULTS: The median and mean follow-up times were 45 and 30 months, respectively (range, 3 to 217 months). The median overall survival (OS) time after diagnosis of BI-ALCL was 13 years, and the OS rate was 93% and 89% at 3 and 5 years, respectively. Patients with lymphoma confined by the fibrous capsule surrounding the implant had better event-free survival (EFS) and OS than did patients with lymphoma that had spread beyond the capsule (P = .03). Patients who underwent a complete surgical excision that consisted of total capsulectomy with breast implant removal had better OS (P = .022) and EFS (P = .014) than did patients who received partial capsulectomy, systemic chemotherapy, or radiation therapy. CONCLUSION: Surgical management with complete surgical excision is essential to achieve optimal EFS in patients with BI-ALCL.
PURPOSE: Breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is a rare type of T-cell lymphoma that arises around breast implants. The optimal management of this disease has not been established. The goal of this study is to evaluate the efficacy of different therapies used in patients with BI-ALCL to determine an optimal treatment approach. PATIENTS AND METHODS: In this study, we applied strict criteria to pathologic findings, assessed therapies used, and conducted a clinical follow-up of 87 patients with BI-ALCL, including 50 previously reported in the literature and 37 unreported. A Prentice, Williams, and Peterson model was used to assess the rate of events for each therapeutic intervention. RESULTS: The median and mean follow-up times were 45 and 30 months, respectively (range, 3 to 217 months). The median overall survival (OS) time after diagnosis of BI-ALCL was 13 years, and the OS rate was 93% and 89% at 3 and 5 years, respectively. Patients with lymphoma confined by the fibrous capsule surrounding the implant had better event-free survival (EFS) and OS than did patients with lymphoma that had spread beyond the capsule (P = .03). Patients who underwent a complete surgical excision that consisted of total capsulectomy with breast implant removal had better OS (P = .022) and EFS (P = .014) than did patients who received partial capsulectomy, systemic chemotherapy, or radiation therapy. CONCLUSION: Surgical management with complete surgical excision is essential to achieve optimal EFS in patients with BI-ALCL.
Authors: Marnelli A Bautista-Quach; Auayporn Nademanee; Dennis D Weisenburger; Wengang Chen; Young S Kim Journal: Clin Breast Cancer Date: 2013-12 Impact factor: 3.225
Authors: Tariq N Aladily; L Jeffrey Medeiros; Mitual B Amin; Nisreen Haideri; Dongjiu Ye; Sergio J Azevedo; Jeffrey L Jorgensen; Mariza de Peralta-Venturina; Eid B Mustafa; Ken H Young; M James You; Luis E Fayad; Ann Marie Blenc; Roberto N Miranda Journal: Am J Surg Pathol Date: 2012-07 Impact factor: 6.394
Authors: Daphne de Jong; Wies L E Vasmel; Jan Paul de Boer; Gideon Verhave; Ellis Barbé; Mariel K Casparie; Flora E van Leeuwen Journal: JAMA Date: 2008-11-05 Impact factor: 56.272
Authors: Sameer S Talwalkar; Roberto N Miranda; Jose R Valbuena; Mark J Routbort; Alvin W Martin; L Jeffrey Medeiros Journal: Am J Surg Pathol Date: 2008-09 Impact factor: 6.394
Authors: Anja C Roden; William R Macon; Gary L Keeney; Jeffrey L Myers; Andrew L Feldman; Ahmet Dogan Journal: Mod Pathol Date: 2008-01-25 Impact factor: 7.842
Authors: Tessa L St Cyr; Barbara A Pockaj; Donald W Northfelt; Fiona E Craig; Mark W Clemens; Raman C Mahabir Journal: Plast Surg (Oakv) Date: 2020-05-21 Impact factor: 0.947
Authors: Naoki Oishi; Garry S Brody; Rhett P Ketterling; David S Viswanatha; Rong He; Surendra Dasari; Ming Mai; Hailey K Benson; Christopher A Sattler; Rebecca L Boddicker; Ellen D McPhail; N Nora Bennani; Christin A Harless; Kuldeep Singh; Mark W Clemens; L Jeffrey Medeiros; Roberto N Miranda; Andrew L Feldman Journal: Blood Date: 2018-06-19 Impact factor: 22.113
Authors: Peter G Cordeiro; Paola Ghione; Andy Ni; Qunying Hu; Nivetha Ganesan; Natasha Galasso; Ahmet Dogan; Steven M Horwitz Journal: J Plast Reconstr Aesthet Surg Date: 2020-01-20 Impact factor: 2.740